Project Abstract

UL1: The Oncofertility Consortium

The purpose of this Interdisciplinary Research Consortium is to focus on the fertility threat posed by cancer treatment and to serve as an authoritative voice for research, clinical practice and training that occurs at the intersection of oncology, pediatrics, reproductive science and medicine, biomechanics, materials science, mathematics, social science, bioethics, religion, policy research, reproductive health law, cognitive and learning science in a new discipline called Oncofertility.  We have assembled outstanding scientists, clinicians and scholars to address the following questions: How do we optimally store and recover gonadal tissue (R01A)?  Can we promote primate-derived immature follicle growth and oocyte maturation in a three dimensional environment (R01B and R01C)?  What is the specific fertility threat of the life-preserving cancer drugs (R01C, K01)?  Can we cryopreserve and grow human ovarian follicles (R01A, R01C)?  Can we predict how new cancer drugs will affect fertility (R01C)?  What are the ethical and legal concerns surrounding the use of advanced reproductive technologies in cancer patients (R01D)?  What is the cost/benefit analysis of fertility preservation (R01D)?  How do families facing a child’s cancer diagnosis decide whether or not to participate in the ovarian cryopreservation work (R01D)?  What role do healthcare practitioners and religious counsel play in the decision (R01D)?  How do women with cancer share their concerns regarding infertility with their physician and how does their decision impact their lives and relationships after cancer (R01D)?  What are the key concerns and treatment decisions that are made at diagnosis and how does gender, race/ethnicity, socioeconomic and family status factor into the equation (R01D)?  Supporting these studies are a biomaterials core (P30A) and an ovarian tissue collection core (P30B).  Supporting the learning and training programs of this grant are a R25 and a T90/R90.  Collectively, this grant serves as a framework into which this exceptionally exciting, challenging and multifaceted new discipline of oncofertility can be fostered and can, in the end, create new knowledge about the process of ovarian follicle development and provide the medical solution to fertility preservation for women with a fertility-altering cancer diagnosis.  In so doing, oncofertility medical specialists, oncofertility scientists, and oncofertility scholars will, for the first time, provide viable options to women with cancer and other fertility threatening diseases, learn more about the nature and mechanisms of follicle development, and better understand human relationships between health, disease, and interventions that can protect the options for future fertility.

U54: The Center for Reproductive Research at Northwestern University

The goal of this project is to contribute to a more comprehensive understanding of female fertility and infertility.  The purpose of our center is to explore ovarian follicle dynamics from the perspective of structure-function relationships of the follicle unit and the hormones that regulate it.  The benchmark of this program is the facilitation of basic biological, biochemical and biophysical findings to clinical care by bringing experts in engineering, biophysics and structural biology together with reproductive endocrinologists and clinical investigators.  This model has been used to explore the relationship between the holo-follicular structure and its ability to sense and respond appropriately to endocrine hormones and paracrine acting factors (inhibin and activin) and made significant new observations about how these mechanisms are regulated biophysically.  We have solved four major hormone structures at the atomic level and the structure of a transcription factor bound to DNA.  We also developed an in vitro follicle maturation system that supports immature follicle growth, oocyte maturation and the birth of live, healthy offspring.  By all measures, the first four years of this center have been productive and effective in translating the work from basic reproductive biology to biophysics, and biomaterials to the bedside.  The projects proposed for the next five years of work are innovative and again focus on major questions in reproductive science using a structure function approach.  Our scientists and clinical investigators work as a highly effective team to ensure the timely, bidirectional transfer of information from clinical problem to the bench and back.  To accomplish our goals, four projects are proposed.  It is known that fertility and oocyte quality diminish with age and oocytes from older women frequently have abnormal meiotic spindles, including abnormal chromosome alignment and microtubular matrix composition and aneuploidy.  Lonnie Shea and team (Project 1) developed an in vitro follicle maturation system, and attractive model for exploring age-related oocyte health.  They will test the hypothesis that oocyte abnormalities arise from lack of coordinated growth of the holo-follicular complex.  Kelly Mayo and Ishwar Radhkrishnan (Project II) will continue their exploration of transcription factor interactions that direct hormone-dependent gene expression in the granulosa cell.  Specifically they will ask how SF-1 and LRH-1 nuclear receptors regulate inhibin α-subunit gene expression at the molecular level in conjunction with the camp-dependent factor CREB and the ovarian factors GATA-4 and GATA-6.  Project II is led by Ted Jardetzky, who is studying the atomic structure of TGF-β superfamily ligands in complex with regulating binding proteins.  He is specifically interested in oocyte-derived GDF-9 and BMP-15, which control follicle development.  Finally, Project IV will examine the relationship of structure rigidity to follicular function and is a collaboration between Teresa Woodruff and Andrea Dunaif.  By combining basic biochemical, biomaterial, and biophysical approaches with medicine, we will remain at the forefront of new discoveries in the structure-function relationships of reproductive biology.  Moreover, each of our continuing projects reaffirms our commitment to translate our findings to the bedside, and thereby contribute to the overall health of women.

W. M. Keck Foundation Medical Research Award: The Inorganic Signature of Life

In 2007, Dr. Teresa Woodruff and colleagues at Northwestern University and the University of Chicago received the prestigious Medical Research Award from the W. M. Keck Foundation.  The research team is composed of reproductive biologists, synthetic chemists and imaging specialists whose common objective is to understand the process of fertilization from a novel, interdisciplinary perspective.

Keck Team during the Site Visit in 2007

Members of the Keck Team in 2007.

Principal investigators in this endeavor include Dr. Teresa Woodruff (Northwestern University), Dr. Thomas O'Halloran (Northwestern University), Dr. Vinayak Dravid (Northwestern University) and Dr. Jonathan Silverstein (University of Chicago).  W. M. Keck Graduate Scholars Alison Kim and Richard Ahn are spearheading the research effort.  The team recently welcomed graduate students Miranda Bernhardt and Betty Kong.

Until recently, the transition metals, such as iron, copper, and zinc, have been overlooked by biologists as integral components of a cell.  In fact, the concentrations of the transition metals in any given cell are carefully controlled by a vast network of membrane-bound and cytoplasmic proteins.  The Keck research team is studying the physiological role of these metals within the context of the egg, the "mother cell": the single cell from which all cells of the body originate.

Keck:Oocyte-to-embryo transition

The stage of the egg's life cycle that is being investigated by the Keck research team

The research team is currently imaging the cellular dynamics of the transition metals by a variety of imaging methods, primarily live-cell confocal microscopy and electron microscopy.  Northwestern University is proud to house a unique scanning transmission electron microscope (STEM) that is equipped with two detectors for energy-dispersive spectroscopy (EDS), which gives an unprecendented collection angle of ~0.8 Sr.  This enables our research team to image notoriously difficult-to-image metals such as zinc at the extremely high resolution provided by electron microscopy.

Check back often for research updates and achievements!

Related links:

K12: Career Development in Women’s Health (The BIRCWH Program)

This application requests support to establish a BIRCWH Program at Northwestern University titled, Career Development in Women’s Health (CDWH).  This program will be used to develop a group of independent, tenure track scientists with backgrounds in clinical medicine or basic science disciplines whose research will address high priority areas relevant to women’s health.  We have identified five focus areas that have been historically strong within Northwestern and that are fundamental to the understanding and treatment of women’s health and disease – differences in cardiovascular disease risk; ovarian biology, obstetrical and gynecological disorders; sex differences in sleep and rheumatology and osteoporosis.  In order to develop expertise outside the Ob-Gyn specialty, faculty members who have interdisciplinary training in basic reproductive science and gender-specific disease research must be cultivated.  Northwestern has a longstanding and rich tradition of interdisciplinary excellence in the reproductive sciences and in disorders that affect women, providing a strong foundation upon which the CDWH program will be developed.  In achieving our goal, the Career Development in Women’s Health Program will create a focused curriculum, provide strong mentorship and engaged faculty development activities.  The junior faculty trained through this program will be in the vanguard of women’s health research scholarship and it is anticipated that training will expand to an ever-widening group of clinicians and investigators.  The program at Northwestern University is robust, timely and rigorous.  Three key ingredients drive this application and will underlie the success of the candidates: high quality research programs, high expectations and a robust training environment.  The CDWH program at Northwestern University is dedicated to these criteria and to the next generation of clinical investigators and translational scientists who will improve health and allay disease in women and men.

R01 HD037096-11A1: Inhibin actions on reproductive target tissues

The objective of this research is to understand the structural determinants that influence inhibin heterodimer assembly, processing and antagonism of an activin signal.  The most recognized action of inhibin is to suppress FSH production and secretion by the pituitary gonadotrope in vitro and in vivo.  Inhibin levels are regulated during the reproductive cycle to ensure normal FSH-dependent follicle recruitment.  Recent work points to a broader role for inhibin in bone metabolism, regulation of adiposity and as a marker of fetal disease.  Little is known regarding the structure-function relationships that evolved to create the only antagonist pair of ligands in the TGFβ superfamily and why no other antagonists emerged over evolutionary time.  Understanding the underlying structural features of inhibin will permit a better understanding of its ability to function as an endocrine hormone and as an activin antagonist.

Inhibin is a dimeric glycoprotein consisting of two subunits (α- and either βA or βB) that form isomers called inhibin A and inhibin B.  The ovarian granulosa cell produces both ligands, whereas inhibin B is the dominant form produced by the Sertoli cells.  Loss of inhibins at the time of menopause in women, following Sertoli damaging chemotherapy in men, or by experimental interventions leads to a prodigious increase in FSH production, indicating that these ligands are central to FSH restraint in an endocrine manner.  We have shown that the cellular machinery that regulates inhibin biosynthesis and processing is important to inhibin action and now hypothesize that biological regulation of inhibin is encoded in the primary and tertiary structure of the hormone and that these protein codes can be solved both functionally and at the structural levels.  Toward this end, we now have crystals of inhibin with its binding receptor (ActRIIB) and the inhibin binding domain of betaglycan (tZP).  This is an exciting development.  This work is essential to our understanding of the biological activity of this ligand, and can be instructive regarding the development of new antagonistic biologics that can control other members of the TGFβ superfamily.  There are three interrelated experimental aims in this proposal that will address the central hypothesis.  The aims rely on sophisticated and innovative biochemical, cell biological, biophysical, and structural methods.  These studies are expected to provide insight into the control of inhibin action and to a more complete understanding of normal fertility and the mechanisms that underlie reproductive diseases in women resulting from inappropriate hormone action.

NIH R01 HD044464-06: Regulation of Reproductive Function by Activin

The most recognized action of activin is to stimulate follistatin-stimulating hormone (FSH) production by the pituitary gonadotrope in vitro and in vivo.  Our work in the past five years has led to a consolidated model of activin-controlled pituitary FSH regulation and an expansion of our understanding regarding the species-specified role of activin in the gonadtropin surge spacing.  We were also the first group to solve the structure of activin together with its binding receptor (ActRIIB) and a major bioneutralizing protein, follistatin (FST).  While these are major advancements in our understanding of activin signaling, there are still fundamental gaps in our knowledge about the independent roles of activin A and B and the duration and modification of their respective signaling cascades.  Our preliminary data show that activin B engages the type I receptors ALK4 and ALK7, while activin A is restricted to ALK4.  This receptor distinction results in Smad2, Smad3, and Smad1 phosphorylation downstream of activin B, while activin A signals are confined to Smads 2 and 3.  Moreover, FST binds activin B with lower affinity than activin A.  Taken together, our data suggest that both the cell signaling and extracellular bioneutralization of these two ligands differs.  These differences are important because activin B and not activin A controls pituitary FSH biosynthesis.  Finally, new work from our lab reveals differential degradation pathways of the Smads, revealing a new level of cellular control over gene networks in tissue targets. The central hypothesis that we will now test is that multi-component receptor complexes are assembled differentially based on unique structural features of the two activin isoforms and that signaling duration is regulated by receptor internalization, FST binding and clearance, and intracellular Smad activation and processing.  By addressing this hypothesis and its tenets, we will provide further insight into the control of pituitary FSH release and follicle formation and in so doing contribute to our understanding of one of most important peptide hormones in reproductive.

Syndicate content

Northwestern University | Northwestern Calendar: Plan-It Purple | Northwestern Search

Woodruff Lab | 303 E Superior Street, Suite 10-121, Chicago Illinois 60611 | Phone: 312-503-2504  

World Wide Web Disclaimer | University Policy Statements | © 2011 Northwestern University